

# Influenza Vaccine Products for the 2017–2018 Influenza Season

Manufacturer	Trade Name (vaccine abbreviation) <sup>1</sup>	How Supplied	Mercury Content (mcg Hg/0.5mL)	Age Group	Vaccine Product Billing Code <sup>2</sup>	
					CPT	Medicare
AstraZeneca	FluMist <sup>3</sup> (LAIV4)	0.2 mL (single-use nasal spray)	0	2 through 49 years	90672	90672
GlaxoSmithKline	Fluarix (IIV4)	0.5 mL (single-dose syringe)	0	3 years & older	90686	90686
ID Biomedical Corp. of Quebec, a subsidiary of GlaxoSmithKline	FluLaval (IIV4)	0.5 mL (single-dose syringe)	0	6 months & older	90686	90686
		5.0 mL (multi-dose vial)	<25	6 months & older	90688	90688
Protein Sciences Corp.	Flublok (RIV3)	0.5 mL (single-dose vial)	0	18 years & older	90673	90673
	Flublok (RIV4)	0.5 mL (single-dose syringe)	0	18 years & older	90682	90682
Sanofi Pasteur, Inc.	Fluzone (IIV4)	0.25 mL (single-dose syringe)	0	6 through 35 months	90685	90685
		0.5 mL (single-dose syringe)	0	3 years & older	90686	90686
		0.5 mL (single-dose vial)	0	3 years & older	90686	90686
		5.0 mL (multi-dose vial)	25	6 through 35 months	90687	90687
		5.0 mL (multi-dose vial)	25	3 years & older	90688	90688
	Fluzone High-Dose (IIV3-HD)	0.5 mL (single-dose syringe)	0	65 years & older	90662	90662
Fluzone Intradermal (IIV4-ID)	0.1 mL (single-dose microinjection system)	0	18 through 64 years	90630	90630	
Seqirus	Afluria (IIV3)	0.5 mL (single-dose syringe)	0	5 years & older <sup>4</sup>	90656	90656
		5.0 mL (multi-dose vial)	24.5		90658	Q2035
	Afluria (IIV4)	0.5 mL (single-dose syringe)	0	5 years & older <sup>4</sup>	90686	90686
		5.0 mL (multi-dose vial)	24.5		90688	90688
	Fluad (aIIV3)	0.5 mL (single-dose syringe)	0	65 years & older	90653	90653
	Fluvirin (IIV3)	0.5 mL (single-dose syringe)	≤1	4 years & older	90656	90656
		5.0 mL (multi-dose vial)	25		90658	Q2037
	Flucelvax (ccIIV4)	0.5 mL (single-dose syringe)	0	4 years & older	90674	90674
		5.0 mL (multi-dose vial)	25		90749/90756 <sup>5</sup>	Q2039/90756 <sup>6</sup>

## FOOTNOTES

- IIV3/IIV4 = egg-based trivalent/quadrivalent inactivated influenza vaccine (injectable); where necessary to refer to cell culture-based vaccine, the prefix “cc” is used (e.g., ccIIV3/ccIIV4); RIV3/RIV4 = trivalent/quadrivalent recombinant hemagglutinin influenza vaccine (injectable); aIIV3 = adjuvanted trivalent inactivated influenza vaccine.
- An administration code should always be reported in addition to the vaccine product code. Note: Third party payers may have specific policies and guidelines that might require providing additional information on their claim forms.
- Live attenuated influenza vaccine (LAIV4; FluMist) is not recommended by CDC’s Advisory Committee on Immunization Practices for use in the U.S. for the 2017–18 influenza season.
- Afluria is approved by the Food and Drug Administration for intramuscular administration with the PharmaJet Stratis

Needle-Free Injection System for persons age 18 through 64 years.

- CPT code 90756 was released on July 1, 2017 for implementation on January 1, 2018. Payers may implement the code based on beneficiaries’ needs any time after the code’s release. The CPT Editorial Panel allotted a 6-month period to allow payers adequate time to prepare their systems; however, processing periods for individual payers may accommodate a more abbreviated timeframe.
- The Centers for Medicare & Medicaid Services (CMS) will implement vaccine code 90756 on January 1, 2018. Before January 1, 2018, claims should use the HCPCS (Healthcare Common Procedure Coding System) Q2039 when billing Medicare.